Fluicell AB (publ) ("Fluicell" or the "Company") has today entered into an exclusive and global license and development agreement with Ambusol AB (publ) ("Ambusol"), which includes the use of Fluicell's microflow platform Nexocyte, as well as the development of a new catheter technology adapted for Ambusol, for the treatment of cancer. The agreement provides Fluicell with up to SEK 142 million, divided into SEK 1.5 million in upfront payments, SEK 29 million in ongoing license payments and up to SEK 111.5 million in the form of milestone payments upon achieved results, divided into five cancer indications. The research and development work that will be conducted by Fluicell, for the adaptation of Fluicell's technology for the purpose, will be done at market remuneration from Ambusol. Finally, Fluicell receives royalties on future treatment sales.
Through the agreement with Fluicell, Ambusol obtains an exclusive global license to apply and commercialize Fluicell's liquid flow control technology/patent portfolio for therapeutic use. A total of five cancer indications are covered, with a first application in glioblastoma and with prostate, breast, skin and pancreatic cancer as subsequent application areas. The collaboration also includes the development and adaptation of Fluicell's technology for delivery of Ambusol's medical substance directly into the tumor, in accordance with Ambusol's treatment concept, aimed at removing cancer cells, unwanted immune cells, cancer cell fragments and other cellular oncogenic debris with ultra-high precision.
"It is with great joy that we today announce that we have entered into a global and exclusive agreement with Ambusol regarding technology for cancer treatment. This agreement means that we are now achieving one of our main goals –to sign commercial agreements in new disease areas. Fluicell's patented technology offers unique opportunities to control fluid flow and drug delivery with ultra-high precision and through the collaboration with Ambusol we further strengthen our position as a leading provider of unique treatment solutions targeting serious disease", says Carolina Trkulja, CEO of Fluicell.
"Ambusol is an excellent match for Fluicell, with long experience in cancer research and with an innovative treatment solution for glioblastoma that has already shown great potential in clinical trials. We look forward to combining our technologies and taking this important step forward to develop transformative therapies for a patient group in great need of new better treatments," concludes Carolina Trkulja.
"Ambusol has extensive research experience and a very powerful approach to treating cancer. Through the collaboration and license agreement with Fluicell, we have a unique opportunity to further strengthen our treatment concept and create a completely new type of cancer therapy. In addition to the possibility of generating new treatments, the technical solutions and innovations that will be added during the collaboration, and which are specific to Ambusol's cancer indications, will be owned by Ambusol and will be continuously protected through further patent applications. Together, Ambusol and Fluicell have an outstanding opportunity to address the significant unmet care needs of people living with these cancers and we look forward to combining our knowledge and experience together," says Maximilian Telander, CEO of Ambusol.
As a first step, the collaboration is focused on optimizing and improving the current treatment solution for glioblastoma, an aggressive form of brain tumor with a high unmet need for care and very high mortality, which affects approximately 300,000 people globally annually. The market for the treatment of glioblastoma amounted to approximately SEK 35 billion in 2024 and is expected to grow to just over SEK 80 billion by 2034. "Glioblastoma is a form of cancer that Ambusol is well acquainted with and where our method has shown great potential in clinical studies. We therefore see this as a natural first area to take our treatment solution through clinical phase and towards commercialization," concludes Maximilian Telander.
About Ambusol
Ambusol AB (publ) is an innovative clinical-stage medical technology company, founded by Professor Emeritus Gunnar Ronquist, who works at Uppsala University Hospital and who has dedicated his life to researching and finding innovative solutions that increase survival and improve the lives of patients with cancer. The company focuses on developing and making available new, more effective and gentle treatment methods for patients. Glioblastoma, an aggressive form of brain tumor with a very high mortality rate, is Ambusol's initial focus, followed by prostate, breast, skin, and pancreatic cancer.
The goal is to improve the quality of life and prolong the lives of those affected, by offering an alternative treatment method that reduces the suffering that traditional treatments with chemotherapy and radiotherapy often entail.